Chidamide for intermediate-to-high-risk myelodysplastic syndromes
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a pill called chidamide for people with a bone marrow condition called myelodysplastic syndromes (MDS). It may help improve blood counts and reduce the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older.
- You have been diagnosed with myelodysplastic syndromes (MDS), a condition where the bone marrow doesn't make enough healthy blood cells.
- Your MDS is considered intermediate or high risk, meaning it may progress to a more serious condition.
- You have had low blood counts for at least 4 months (unless you have certain chromosome changes or increased blasts).
- You are generally able to care for yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
This trial tests an experimental drug called BL-M11D1 for people with myelodysplastic syndromes (MDS) that has come back or not improved with standard treatment. The drug targets a protein called CD33 on cancer cells and may help reduce the number of abnormal cells in the bone marrow.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.